UPFRONT™ -
A Clinical Trial for
Patients with Newly
Diagnosed Multiple
Myeloma

Multiple myeloma is the second most common cancer of the blood. The UPFRONT™ trial will study the addition of VELCADE^® to 3 active drug therapies presently being used to treat multiple myeloma.

To learn more about the
Millennium drug used in this
trial, please CLICK HERE

About the
UPFRONT Trial
Patient Resources
CLICK HERE
to See If You May
Qualify, or Call
1-877-MPI-DRUG (1-877-674-3784)

For full prescribing information for VELCADE, please CLICK HERE :

The website is intended only for residents of the United States. This website offers resources that may help answer some of your questions, or those of your family or caregivers, about the UPFRONT clinical trial. You should not make decisions about participating in any trial without first speaking to your doctor. You should talk to your doctor about any questions or concerns you may have about this trial or about your treatment options.

UPFRONT™ -A Clinical Trial forPatients with NewlyDiagnosed MultipleMyeloma

For full prescribing information for VELCADE, please CLICK HERE :

UPFRONT™ -
A Clinical Trial for
Patients with Newly
Diagnosed Multiple
Myeloma